Bayer is showcasing at the RSNA 2024 several newly U.S. Food and Drug Administration (FDA) 510(k) cleared products, announcing new clinical data for investigational contrast agent gadoquatrane, and an extension of an initiative with Subtle Medical.
The company is highlighting its smart Medrad Centargo CT Injection System, which the FDA cleared less than a month ago, as well as Calantic Digital Solutions, which coordinates third-party app solutions into a single, cloud-based marketplace.
Bayer is announcing data from two clinical studies on gadoquatrane, an investigational MRI contrast agent in phase-III development.
Bayer and AI med tech firm Subtle Medical announced that they are extending an initiative to develop an investigational AI software in combination with an investigational lower dose of a contrast agent. Bayer also said that it has entered new collaborative agreements with radiology AI technology providers Rad AI, AIRS Medical, Contextflow, GLEAMER, AZmed, Smart Soft Healthcare, and Lucida Medical.
